side effects of glp 1 drugs Exploring the GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning Press Release Page | Press

Abbreviations GLP-1: Glucagon-like peptide-1 GLP-1R: GLP-1 receptor HF: Heart failure LVEDD: Left ventricular end-diastolic dimension LVESD: Left ventricular end-systolic dimension FS: Fractional shortening EF: Ejection fraction LVEDV: Left ventricular end-diastolic volume LVESV: Left ventricular end-systolic volume SV: Stroke volume CO: Cardiac output LVEDP: Left ventricular end-diastolic pressure LVESP: Left ventricular end-systolic pressure +dP/dt: Maximal slope of systolic pressure increment dP/dt: Maximal slope of diastolic pressure decrement LV: Left ventricle ARNA: Afferent renal nerve activity MAP: Mean arterial pressure HR: Heart rate qRT-PCR: Quantitative reverse-transcription polymerase chain reaction TBST: Tris-buffered saline with tween 20 RSNA: Renal sympathetic nerve activity T-RDN: Total renal denervation A-RDN: Afferent renal denervation CGRP: Calcitonin gene-related peptide TH: Tyrosine hydroxylase CrCl: Creatinine clearance ERNA: Efferent renal nerve activity PVN: Paraventricular nucleus ARB: Angiotensin receptor blocker SGLT2: Sodiumglucose cotransporter 2 References Holst JJ

The peptide does not eliminate side effects entirely, but the severity reduction allows more users to reach therapeutic doses

The peptide research landscape has matured significantly since 2020

Dial a small dose, hold the pen upright, and press the button to release a drop of medication